Immune checkpoint inhibitors (ICIs), including antibodies against programmed cell death protein-1 (PD-1) or its ligand (PDL-1) and cytotoxic T-lymphocyte antigen-4 (CTLA-4) have proven to enhance anti-tumor immunity and efficacy in several cancers. Here, PDCD1 is linked to neoplasm.